Lyra Therapeutics (LYRA) Shares Outstanding (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Shares Outstanding (Entity) of $1.8 million in Q4 2025, up 7.93% on a QoQ basis from $1.6 million in Q3 2025, and up 35.46% YoY from $1.3 million in Q4 2024.
Lyra Therapeutics (LYRA) Shares Outstanding (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Shares Outstanding (Entity) for 7 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.
- Shares Outstanding (Entity) for Q4 2025 came in at $1.8 million, up 35.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.8 million (up 35.46% YoY), and the FY2025 annual result was $1.8 million, up 35.46% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $1.8 million, up from $1.6 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $1.8 million in Q4 2025, with the low at $259255.0 in Q1 2021.
- A 5-year average of $910280.1 and a median of $990906.0 in 2023 frame the typical range for Shares Outstanding (Entity).
- Across the five-year window, Shares Outstanding (Entity) surged 5515.23% in 2021 and rose 0.36% in 2022, its largest moves.
- Lyra Therapeutics' Shares Outstanding (Entity) stood at $260144.0 in 2021, then surged by 144.69% to $636553.0 in 2022, then soared by 79.76% to $1.1 million in 2023, then rose by 14.51% to $1.3 million in 2024, then soared by 35.46% to $1.8 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $1.8 million (Q4 2025), $1.6 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 996,086.00 |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 873,528.00 |
| Mar 31, 2023 | 736,655.00 |
| Dec 31, 2022 | 604,714.00 |
| Sep 30, 2022 | 736,527.00 |
| Jun 30, 2022 | 678,929.00 |
| Mar 31, 2022 | 260,176.00 |
| Dec 31, 2021 | 259,722.00 |
| Sep 30, 2021 | 260,030.00 |
| Jun 30, 2021 | 259,837.00 |
| Mar 31, 2021 | 258,911.00 |